Cargando…
Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
We investigated the role of AS03(A) (here AS03), an α-tocopherol oil-in-water emulsion-based adjuvant system, on the long-term persistence of humoral and cell-mediated immune responses to A(H1N1)pdm09 influenza vaccines. In two studies, a total of 261 healthy adults (≤60 years old) were randomized t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461372/ https://www.ncbi.nlm.nih.gov/pubmed/28446441 http://dx.doi.org/10.1128/CVI.00553-16 |
_version_ | 1783242329576964096 |
---|---|
author | van der Most, Robbert G. Clément, Frédéric Willekens, Julie Dewé, Walthère Walravens, Karl Vaughn, David W. Leroux-Roels, Geert |
author_facet | van der Most, Robbert G. Clément, Frédéric Willekens, Julie Dewé, Walthère Walravens, Karl Vaughn, David W. Leroux-Roels, Geert |
author_sort | van der Most, Robbert G. |
collection | PubMed |
description | We investigated the role of AS03(A) (here AS03), an α-tocopherol oil-in-water emulsion-based adjuvant system, on the long-term persistence of humoral and cell-mediated immune responses to A(H1N1)pdm09 influenza vaccines. In two studies, a total of 261 healthy adults (≤60 years old) were randomized to receive two doses of AS03-adjuvanted vaccine containing 3.75 μg of hemagglutinin (HA) or nonadjuvanted vaccine containing 15 μg of hemagglutinin (in study A) or 3.75 μg of hemagglutinin (in study B) 21 days apart. Hemagglutination inhibition (HI) antibody, memory B-cell, and CD4(+)/CD8(+) T-cell responses were characterized up to 1 year following dose 1. We also assessed the effects of age and seasonal influenza vaccination history. AS03-adjuvanted (3.75 μg HA) vaccine and nonadjuvanted vaccine at 15 μg but not at 3.75 μg HA elicited HI antibody responses persisting at levels that continued to meet European licensure criteria through month 12. At month 12, the geometric mean titer for AS03-adjuvanted vaccine was similar to that for nonadjuvanted (15-μg) vaccine in study A (1:86 and 1:88, respectively) and higher than that for nonadjuvanted (3.75-μg) vaccine in study B (1:77 and 1:35, respectively). A(H1N1)pdm09-specific CD4(+) T-cell and B-cell responses were stronger in AS03-adjuvanted groups and persisted only in these groups for 12 months at levels exceeding prevaccination frequencies. Advancing age and a seasonal vaccination history tended to reduce HI antibody and memory B-cell responses and, albeit less consistently, CD4(+) T-cell responses. Thus, AS03 seemed to enhance the persistence of humoral and cell-mediated responses to A(H1N1)pdm09 vaccine, allowing for antigen sparing and mitigating potential negative effects of age and previous seasonal vaccination. (These studies have been registered at ClinicalTrials.gov under registration no. NCT00968539 and NCT00989287.) |
format | Online Article Text |
id | pubmed-5461372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-54613722017-06-27 Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials van der Most, Robbert G. Clément, Frédéric Willekens, Julie Dewé, Walthère Walravens, Karl Vaughn, David W. Leroux-Roels, Geert Clin Vaccine Immunol Clinical Immunology We investigated the role of AS03(A) (here AS03), an α-tocopherol oil-in-water emulsion-based adjuvant system, on the long-term persistence of humoral and cell-mediated immune responses to A(H1N1)pdm09 influenza vaccines. In two studies, a total of 261 healthy adults (≤60 years old) were randomized to receive two doses of AS03-adjuvanted vaccine containing 3.75 μg of hemagglutinin (HA) or nonadjuvanted vaccine containing 15 μg of hemagglutinin (in study A) or 3.75 μg of hemagglutinin (in study B) 21 days apart. Hemagglutination inhibition (HI) antibody, memory B-cell, and CD4(+)/CD8(+) T-cell responses were characterized up to 1 year following dose 1. We also assessed the effects of age and seasonal influenza vaccination history. AS03-adjuvanted (3.75 μg HA) vaccine and nonadjuvanted vaccine at 15 μg but not at 3.75 μg HA elicited HI antibody responses persisting at levels that continued to meet European licensure criteria through month 12. At month 12, the geometric mean titer for AS03-adjuvanted vaccine was similar to that for nonadjuvanted (15-μg) vaccine in study A (1:86 and 1:88, respectively) and higher than that for nonadjuvanted (3.75-μg) vaccine in study B (1:77 and 1:35, respectively). A(H1N1)pdm09-specific CD4(+) T-cell and B-cell responses were stronger in AS03-adjuvanted groups and persisted only in these groups for 12 months at levels exceeding prevaccination frequencies. Advancing age and a seasonal vaccination history tended to reduce HI antibody and memory B-cell responses and, albeit less consistently, CD4(+) T-cell responses. Thus, AS03 seemed to enhance the persistence of humoral and cell-mediated responses to A(H1N1)pdm09 vaccine, allowing for antigen sparing and mitigating potential negative effects of age and previous seasonal vaccination. (These studies have been registered at ClinicalTrials.gov under registration no. NCT00968539 and NCT00989287.) American Society for Microbiology 2017-06-05 /pmc/articles/PMC5461372/ /pubmed/28446441 http://dx.doi.org/10.1128/CVI.00553-16 Text en Copyright © 2017 van der Most et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Clinical Immunology van der Most, Robbert G. Clément, Frédéric Willekens, Julie Dewé, Walthère Walravens, Karl Vaughn, David W. Leroux-Roels, Geert Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials |
title | Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials |
title_full | Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials |
title_fullStr | Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials |
title_full_unstemmed | Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials |
title_short | Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials |
title_sort | long-term persistence of cell-mediated and humoral responses to a(h1n1)pdm09 influenza virus vaccines and the role of the as03 adjuvant system in adults during two randomized controlled trials |
topic | Clinical Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461372/ https://www.ncbi.nlm.nih.gov/pubmed/28446441 http://dx.doi.org/10.1128/CVI.00553-16 |
work_keys_str_mv | AT vandermostrobbertg longtermpersistenceofcellmediatedandhumoralresponsestoah1n1pdm09influenzavirusvaccinesandtheroleoftheas03adjuvantsysteminadultsduringtworandomizedcontrolledtrials AT clementfrederic longtermpersistenceofcellmediatedandhumoralresponsestoah1n1pdm09influenzavirusvaccinesandtheroleoftheas03adjuvantsysteminadultsduringtworandomizedcontrolledtrials AT willekensjulie longtermpersistenceofcellmediatedandhumoralresponsestoah1n1pdm09influenzavirusvaccinesandtheroleoftheas03adjuvantsysteminadultsduringtworandomizedcontrolledtrials AT dewewalthere longtermpersistenceofcellmediatedandhumoralresponsestoah1n1pdm09influenzavirusvaccinesandtheroleoftheas03adjuvantsysteminadultsduringtworandomizedcontrolledtrials AT walravenskarl longtermpersistenceofcellmediatedandhumoralresponsestoah1n1pdm09influenzavirusvaccinesandtheroleoftheas03adjuvantsysteminadultsduringtworandomizedcontrolledtrials AT vaughndavidw longtermpersistenceofcellmediatedandhumoralresponsestoah1n1pdm09influenzavirusvaccinesandtheroleoftheas03adjuvantsysteminadultsduringtworandomizedcontrolledtrials AT lerouxroelsgeert longtermpersistenceofcellmediatedandhumoralresponsestoah1n1pdm09influenzavirusvaccinesandtheroleoftheas03adjuvantsysteminadultsduringtworandomizedcontrolledtrials |